112380-21-9

Basic information

• Product Name: L-Threonine, N-[(1,1-dimethylethoxy)carbonyl]-, methyl ester, 4-methylbenzenesulfonate (ester)
• CAS NO: 112380-21-9
• Molecular Formula: C17H25NO7S
• Molecular Weight: 387.454
• Mol File: 112380-21-9.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: L-Threonine, N-[(1,1-dimethylethoxy)carbonyl]-, methyl ester, 4-methylbenzenesulfonate (ester)(CAS DataBase Reference)
• NIST Chemistry Reference: L-Threonine, N-[(1,1-dimethylethoxy)carbonyl]-, methyl ester, 4-methylbenzenesulfonate (ester)(112380-21-9)
• EPA Substance Registry System: L-Threonine, N-[(1,1-dimethylethoxy)carbonyl]-, methyl ester, 4-methylbenzenesulfonate (ester)(112380-21-9)

Safety Data

• Hazardous Substances Data: 112380-21-9(Hazardous Substances Data)

Upstream product

• 2592-18-9 N-(t-Butyloxycarbonyl)-L-threonine 
• 98-59-9 p-toluenesulfonyl chloride 
• 2592-18-9 Boc-Thr-OH 
• 60538-19-4 N-(tert-butoxycarbonyl)-l-threonine methyl ester 

Downstream Products

• 112380-23-1 (2R,3S)-3-Benzylsulfanyl-2-tert-butoxycarbonylamino-butyric acid methyl ester 

Relevant articles and documents

Simple and efficient synthesis of allo- and threo-3,3′-dimethylcystine derivatives in enantiomerically pure form

A simple and efficient method for the synthesis of allo- and threo-3,3′-dimethylcystine derivatives is reported. Various tosyl and bromo derivatives of Cbz-, Boc-, and Fmoc- protected threonine methyl esters have been prepared and subjected to nucleophili

Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors

The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Penicillin Biosynthesis: Active Site Mapping with L-&α-Aminoadipoyl-(C-methyl-L-cysteinyl)-D-valine Variants

A series of structural variants of the cysteinyl moiety of the natural precursor of penicillins, δ-(L-α-aminoadipoyl)-L-cysteinyl-D-valine, have been synthesised and their effectiveness as substrates for the enzyme isopenicillin N synthetase has been eval